CGTLive®’s Weekly Rewind – August 9, 2024

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Indapta to Evaluate g-NK Therapy in Trial for Progressive Multiple Sclerosis

The trial evaluating the safety and tolerability of IDP-023 will be led by Stanford and UCSF.

2. Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy

The cofounder and chief science officer of Longeveron discussed working to show potential benefits in a follow-up phase 3 trial.

3. FDA Modifies CAR-T Risk Strategies to Lower Healthcare Burden

A recent study also recommended a shorter, more flexible monitoring period post-CAR–T therapy.

4. David Dimmock, MBBS, on a Promising Case Study of Ultra-Rare, AI-Guided, ASO Development

The chief medical officer at Creyon Bio discussed findings from a treated patient with a TNP02 missense mutation.

5. Pivotal Bria-IMT Trial Hopes to Support BLA for Advanced Metastatic Breast Cancer

BriaCell initiated the pivotal phase 3 BRIA-ABC trial in October 2023.